Patent classifications
C07D231/22
STEREOSELECTIVE PROCESS TO OBTAIN (Z)-5-CYCLYLOXY-2-[(E)-METHOXYIMINO]-3-METHYL-PENT-3-ENIC ACID METHYL AMIDES USING E,Z-ISOMER MIXTURE OF AND INTERMEDIATES THEREOF
The present invention relates to a process for preparation of intermediates (Z,2E)-5-hydroxy-2-methoxyimino-N-methyl-pent-3-enamides from 4-substituted 5-meth-oxyimino-2H-pyran-6-ones and their processing for example to (Z)-5-cyclyloxy-2-[(E)-methoxyimino]-3-methyl-pent-3-enic acid methyl amides. The invention also relates to a process for preparation of 4-substituted 5-imino-2H-pyran-6-ones and to novel intermediates for the preparation of fungicidal (Z)-5-cyclyloxy-2-[(E)-methoxyimino]-3-methyl-pent-3-enic acid methyl amides.
Use of sigma ligands in diabetes type-2 associated pain
The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat type-2 diabetes-associated pain and related symptoms. ##STR00001##
Use of sigma ligands in diabetes type-2 associated pain
The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat type-2 diabetes-associated pain and related symptoms. ##STR00001##
Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
The invention refers to the use of a sigma ligand, preferably a sigma ligand of formula (I), to prevent or treat emesis induced by a chemotherapeutic agent or radioactivity, especially emesis induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs. ##STR00001##
Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
The invention refers to the use of a sigma ligand, preferably a sigma ligand of formula (I), to prevent or treat emesis induced by a chemotherapeutic agent or radioactivity, especially emesis induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs. ##STR00001##
Process for the preparation of Pyraclostrobin
The present invention relates to a novel and improved process for preparation of methyl [2-({[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy}methyl)phenyl]methoxycarbamate (Pyraclostrobin) of formula (I) in free form or in agrochemically acceptable salt form useful as a pest control agent starting from methyl [2-({[1-(4-chlorophenyl)-1-H-pyrazol-3-yl]oxy}methyl)phenyl]hydroxycarbamatein simple manner and in high purity and good yield.
Process for the preparation of Pyraclostrobin
The present invention relates to a novel and improved process for preparation of methyl [2-({[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy}methyl)phenyl]methoxycarbamate (Pyraclostrobin) of formula (I) in free form or in agrochemically acceptable salt form useful as a pest control agent starting from methyl [2-({[1-(4-chlorophenyl)-1-H-pyrazol-3-yl]oxy}methyl)phenyl]hydroxycarbamatein simple manner and in high purity and good yield.
EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE
The present invention provides a novel prodrug of an edaravone compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same as an active ingredient, and a use thereof in treatment or alleviation of neurodegenerative and/or motor neuron disease.
EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE
The present invention provides a novel prodrug of an edaravone compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same as an active ingredient, and a use thereof in treatment or alleviation of neurodegenerative and/or motor neuron disease.
Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease
The present invention provides a novel prodrug of an edaravone compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same as an active ingredient, and a use thereof in treatment or alleviation of neurodegenerative and/or motor neuron disease.